Please ensure Javascript is enabled for purposes of website accessibility

Investors & Media

Corporate Profile

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases.

Stock Quote

  • Change
  • Volume
  • Today's Open
  • Previous Close
  • Today's High
  • Today's Low
  • 52 Week High
  • 52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Investor Contact
Meredith Kaya
(617) 599-8178

Media Relations
Lissa Pavluk
(617) 977-6764